Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia
A high prevalence rate of macrolide-resistant Mycoplasma pneumoniae (MRMP) has been reported in Asia. We performed a systematic review and meta-analysis to investigate the effect of macrolide resistance on the manifestations and clinical judgment during M. pneumoniae infections. We found no differen...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2020-07-01
|
| Series: | Emerging Infectious Diseases |
| Subjects: | |
| Online Access: | https://wwwnc.cdc.gov/eid/article/26/7/20-0017_article |
| _version_ | 1828332029693919232 |
|---|---|
| author | Yu-Chin Chen Wei-Yun Hsu Tu-Hsuan Chang |
| author_facet | Yu-Chin Chen Wei-Yun Hsu Tu-Hsuan Chang |
| author_sort | Yu-Chin Chen |
| collection | DOAJ |
| description | A high prevalence rate of macrolide-resistant Mycoplasma pneumoniae (MRMP) has been reported in Asia. We performed a systematic review and meta-analysis to investigate the effect of macrolide resistance on the manifestations and clinical judgment during M. pneumoniae infections. We found no difference in clinical severity between MRMP and macrolide-sensitive Mycoplasma pneumoniae (MSMP) infections. However, in the pooled data, patients infected with MRMP had a longer febrile period (1.71 days), length of hospital stay (1.61 day), antibiotic drug courses (2.93 days), and defervescence time after macrolide treatment (2.04 days) compared with patients infected with MSMP. The risk of fever lasting for >48 hours after macrolide treatment was also significantly increased (OR 21.24), and an increased proportion of patients was changed to second-line treatment (OR 4.42). Our findings indicate diagnostic and therapeutic challenges after the emergence of MRMP. More precise diagnostic tools and clearly defined treatment should be appraised in the future. |
| first_indexed | 2024-04-13T21:01:19Z |
| format | Article |
| id | doaj.art-e4304d75b0914b12b56c354f7a3b048e |
| institution | Directory Open Access Journal |
| issn | 1080-6040 1080-6059 |
| language | English |
| last_indexed | 2024-04-13T21:01:19Z |
| publishDate | 2020-07-01 |
| publisher | Centers for Disease Control and Prevention |
| record_format | Article |
| series | Emerging Infectious Diseases |
| spelling | doaj.art-e4304d75b0914b12b56c354f7a3b048e2022-12-22T02:30:09ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592020-07-012671382139110.3201/eid2607.200017Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired PneumoniaYu-Chin ChenWei-Yun HsuTu-Hsuan ChangA high prevalence rate of macrolide-resistant Mycoplasma pneumoniae (MRMP) has been reported in Asia. We performed a systematic review and meta-analysis to investigate the effect of macrolide resistance on the manifestations and clinical judgment during M. pneumoniae infections. We found no difference in clinical severity between MRMP and macrolide-sensitive Mycoplasma pneumoniae (MSMP) infections. However, in the pooled data, patients infected with MRMP had a longer febrile period (1.71 days), length of hospital stay (1.61 day), antibiotic drug courses (2.93 days), and defervescence time after macrolide treatment (2.04 days) compared with patients infected with MSMP. The risk of fever lasting for >48 hours after macrolide treatment was also significantly increased (OR 21.24), and an increased proportion of patients was changed to second-line treatment (OR 4.42). Our findings indicate diagnostic and therapeutic challenges after the emergence of MRMP. More precise diagnostic tools and clearly defined treatment should be appraised in the future.https://wwwnc.cdc.gov/eid/article/26/7/20-0017_articleMycoplasma pneumoniaemacrolide resistancechildrenpneumoniabacteriaAsia |
| spellingShingle | Yu-Chin Chen Wei-Yun Hsu Tu-Hsuan Chang Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia Emerging Infectious Diseases Mycoplasma pneumoniae macrolide resistance children pneumonia bacteria Asia |
| title | Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia |
| title_full | Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia |
| title_fullStr | Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia |
| title_full_unstemmed | Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia |
| title_short | Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia |
| title_sort | macrolide resistant mycoplasma pneumoniae infections in pediatric community acquired pneumonia |
| topic | Mycoplasma pneumoniae macrolide resistance children pneumonia bacteria Asia |
| url | https://wwwnc.cdc.gov/eid/article/26/7/20-0017_article |
| work_keys_str_mv | AT yuchinchen macrolideresistantmycoplasmapneumoniaeinfectionsinpediatriccommunityacquiredpneumonia AT weiyunhsu macrolideresistantmycoplasmapneumoniaeinfectionsinpediatriccommunityacquiredpneumonia AT tuhsuanchang macrolideresistantmycoplasmapneumoniaeinfectionsinpediatriccommunityacquiredpneumonia |